CN109045023A - A kind of dog compound Fei Luokao former times dry suspensoid agent and preparation method thereof - Google Patents
A kind of dog compound Fei Luokao former times dry suspensoid agent and preparation method thereof Download PDFInfo
- Publication number
- CN109045023A CN109045023A CN201810995280.2A CN201810995280A CN109045023A CN 109045023 A CN109045023 A CN 109045023A CN 201810995280 A CN201810995280 A CN 201810995280A CN 109045023 A CN109045023 A CN 109045023A
- Authority
- CN
- China
- Prior art keywords
- former times
- fei luokao
- dry suspensoid
- dog
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Botany (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to veterinary drug pharmaceutical preparation preparation technical fields, and in particular to a kind of prescription and preparation method thereof of dog compound Fei Luokao former times dry suspensoid agent.It is a feature of the present invention that dog compound Fei Luokao former times dry suspensoid agent main component and its mass percent are as follows: Fei Luokao former times 0.25 ~ 0.75%, Glucosamine Sulphate 1.12 ~ 1.32%, calcitriol 1.0 ~ 1.5 × 10‑6%, suspending agent 0.8 ~ 4%, surfactant 0.25 ~ 1%, glidant 0.5 ~ 1%, corrigent 1 ~ 3%, filler to 100%.Part main ingredient and auxiliary material are used into particle ball mill grinding, then equivalent other auxiliary materials that progressively increase dispense after mixing.Dog of the present invention compound Fei Luokao former times dry suspensoid agent, the good feature of existing solid pharmaceutical preparation convenient transportation, stability, and there is liquid preparation easily to absorb, the high advantage of bioavilability.In addition, overcoming the problems such as poor powder flowbility, granular pattern dry suspensoid agent complex process and granulation are easily agglomerated.It can be cooperateed with when treating dog arthritis and play anti-inflammatory, analgesia, promote the effect of regenerating bone or cartilage, relative to independent medication, had the characteristics that safer, more efficient.
Description
Technical field
The present invention relates to pharmaceutic preparation for livestock technical fields, and in particular to a kind of dog compound Fei Luokao former times dry suspensoid agent and
Preparation method.
Background technique
The pet quantity of China increases 900% between 10 years of 2003 to 2016.Chinese pet in 2017
Quantity has increased to 1.68 hundred million or so, and pet industry sales volume breaches 130,000,000,000 yuan.In recent years, the common disease of pet dog it
The disease incidence of one canine osteoarthritis is in rising trend, is that one kind is broken by wound, joint birth defect, joint deformity, cartilage
It the chronic, progressive disease caused by reasons such as splits or destroys, be mainly spy with periarticular change in organization, inflammation and pain etc.
Sign.Serious damage is caused to the health and welfare of pet dog.
Fei Luokao former times (Firocoxib) is a kind of important non-steroidal anti-inflammatory drugs for animals, main by selectively inhibiting
The synthesis of cyclooxygenase-2 (COX-2), come block arachidonic acid to be converted into prostaglandin and play it is antipyretic, analgesia, it is anti-inflammatory
Effect.Ratify through FDA, Fei Luokao former times is mainly used for treating horse class osteoarthritis and the acute and chronic pain as caused by clinical operation
Pain and inflammation, China has dog Fei Luokao former times piece on the market at present.Most of non-steroidal anti-inflammatory drugs are to COX-2 and COX-1
Selectivity it is poor, cause the prostaglandin to shield in gastrointestinal mucosa synthesis also suppressed, thus easily lead to digestion
The adverse reaction of system.Unlike other non-steroidal anti-inflammatory drugs, Fei Luokao former times can inhibit COX-2 with high selectivity, interior
Clothes easily absorb, and have very high clinical value.
The anti-inflammatory of Fei Luokao former times, analgesic effect are obvious, but act on less bone articular cartilage lesion, can not reverse joint
Pathological state.Glucosamine is the intracorporal amino monosaccharide of machine, is proteoglycans synthesis process in body articular cartilage matrix
In important component, supplemented with exogenous Glucosamine both inhibited clostridiopetidase A and proteoglycan degrading enzymatic activity, and blocked knee joint
The pathologic process of degenerative change, but can play it is anti-inflammatory and promote regenerating bone or cartilage the effect of.And calcitriol can pass through complexity
Mechanism come adjust calcium stationary state balance, can slow down osteoarthritis lesion progress in Subchondral bone sclerosis, to articular cartilage have compared with
Strong protective effect.Therefore, theoretical and of the invention clinical practice proves, above-mentioned three kinds of drugs is carried out scientific compatibility, to dog
Osteoarthritis collaboration plays drug effect, and resultant effect is clearly.
Dry suspensoid agent is that powdered or granular formulations are made with proper method in drug by the requirement of suspension, when use
Water is added to be dispersed into the oral solid formulation of suspension rapidly, which has stability good, and oral absorption is good, biological utilisation
The advantages that high is spent, also can avoid the shortcomings that tablet, capsule difficulty are swallowed.Have when in clinic also causes tablet to scratch because feeding is improper
The case of dog, especially young dog esophagus occurs.Dry suspensoid agent is the novel form to grow up on the basis of suspension, than mixed
Suspension has the characteristics of physically better stability, existing solid pharmaceutical preparation, is such as convenient for carrying, convenient transportation, and stability is good etc., again
There is the advantage of liquid preparation, such as conveniently take, absorbs rapid.
Summary of the invention
In view of this, the purpose of the present invention is to provide a kind of dog compound Fei Luokao former times dry suspensoid agents and its preparation side
Method, when treating canine osteoarthritis morbidity, collaboration plays anti-inflammatory, analgesic effect, while promoting regenerating bone or cartilage and Saving cortilage cartilage
The effect of.
In order to achieve the above objectives, the invention provides the following technical scheme:
The invention discloses dog compound Fei Luokao former times dry suspensoid agent, the main components and its mass percent of said preparation are as follows:
Fei Luokao former times 0.25%；
Glucosamine Sulphate 1.12%；
Calcitriol 1.5 × 10-6%；
Suspending agent 0.8 ~ 4%；
Surfactant 0.25 ~ 1%；
Glidant 0.5 ~ 1%；
Corrigent 1 ~ 3%；
Filler is to 100%.
Further, the suspending agent is hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, carboxylic first
One or both of base cellulose.
Further, the surfactant is one of dodecyl sodium sulfate, Tween-80, lecithin.
Further, the glidant is one of superfine silica gel powder, talcum powder.
Further, the corrigent is one or both of powdered beef, chicken meal, chicken liver meal, duck liver powder.
Further, the filler is one of soluble starch and glucose.
Invention additionally discloses the dog preparation methods of compound Fei Luokao former times dry suspensoid agent, and former, auxiliary material is crossed 100 respectively
Mesh mixes well first by Fei Luokao former times, calcitriol and surfactant, is placed in particle ball mill and grinds 1 hour, mistake
120 meshes enter Glucosamine Sulphate with equivalent gradually-increased, suspending agent, glidant, rectify in prescription ratio in this mixture
Taste agent and filler, finally dispense mixture to obtain the final product.
The beneficial effects of the present invention are:
Antiarthritic, arthralgic Fei Luokao former times are promoted the Glucosamine Sulphate of regenerating bone or cartilage by the present invention, increase the storage of bone calcium
The calcitriol to shield to articular cartilage is deposited, reasonable compatibility prescription is carried out, cooperates with and plays when treating canine osteoarthritis
Anti-inflammatory, analgesic effect, while the effect of promote regenerating bone or cartilage and Saving cortilage cartilage.Be prepared into dry suspensoid agent have easily storage,
The shortcomings that the advantages that stability is good, oral absorption is good, bioavilability is high, also avoidable tablet, capsule difficulty are swallowed.In addition,
Using preparation method of the invention, poor powder flowbility, granular pattern dry suspensoid agent complex process and granulation easily agglomeration are also overcomed
The problems such as.
Specific embodiment
It, below will be to preferred reality of the invention in order to keep the purpose of the present invention, technical scheme and beneficial effects clearer
Example is applied to be described in detail.
Embodiment 1
The component and its mass percent of the dog of the present embodiment compound Fei Luokao former times dry suspensoid agent are as follows:
Fei Luokao former times 0.25%；
Glucosamine Sulphate 1.32%；
Calcitriol 1.0 × 10-6%；
Hydroxypropyl methyl cellulose 0.8%；
Dodecyl sodium sulfate 0.5%；
Talcum powder 1%；
Chicken liver meal 1%；
Glucose is to 100%.
The dog of the present embodiment compound Fei Luokao former times dry suspensoid agent the preparation method comprises the following steps: above-mentioned former, auxiliary material is distinguished respectively
It sieves with 100 mesh sieve spare, first by Fei Luokao former times, calcitriol and dodecyl sodium sulfate, mixes well, be placed in particle ball mill
Grinding 1 hour is crossed 120 meshes in prescription ratio in this mixture and is entered the sulfuric acid aminoglucose of recipe quantity with equivalent gradually-increased
Sugar, hydroxypropyl methyl cellulose, talcum powder, chicken liver meal and glucose, finally dispense mixture to obtain the final product.
Embodiment 2
The component and its mass percent of the dog of the present embodiment compound Fei Luokao former times dry suspensoid agent are as follows:
Fei Luokao former times 0.25%；
Glucosamine Sulphate 1.12%；
Calcitriol 1.5 × 10-6%；
Hydroxypropyl methyl cellulose 0.8%；
Carboxymethyl cellulose 1.0%；
Tween-80 1.0%；
Superfine silica gel powder 0.5%；
Chicken meal 2%；
Glucose is to 100%.
The dog of the present embodiment compound Fei Luokao former times dry suspensoid agent the preparation method comprises the following steps: respectively by above-mentioned former, auxiliary material (except spitting
Outside temperature -80) sieve with 100 mesh sieve respectively spare, it first by Fei Luokao former times, calcitriol and Tween-80, mixes well, is placed in particle sphere
It is ground 1 hour in grinding machine, crosses 120 meshes in prescription ratio in this mixture and enter the sulfate of ammoniac of recipe quantity with equivalent gradually-increased
Base glucose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, superfine silica gel powder, chicken meal and glucose, finally by mixture point
It fills to obtain the final product.
Embodiment 3
The component and its mass percent of the dog of the present embodiment compound Fei Luokao former times dry suspensoid agent are as follows:
Fei Luokao former times 0.5%；
Glucosamine Sulphate 1.12%；
Calcitriol 1.5 × 10-6%；
Hydroxypropyl methyl cellulose 0.8%；
Carboxymethyl cellulose 3.0%
Dodecyl sodium sulfate 0.5%；
Superfine silica gel powder 0.5%；
Chicken liver meal 2%；
Glucose is to 100%.
The dog of the present embodiment compound Fei Luokao former times dry suspensoid agent the preparation method comprises the following steps: above-mentioned former, auxiliary material is distinguished respectively
It sieves with 100 mesh sieve spare, first by Fei Luokao former times, calcitriol and dodecyl sodium sulfate, mixes well, be placed in particle ball mill
Grinding 1 hour is crossed 120 meshes in prescription ratio in this mixture and is entered the sulfuric acid aminoglucose of recipe quantity with equivalent gradually-increased
Mixture packing is finally by sugar, hydroxypropyl methyl cellulose, carboxymethyl cellulose, superfine silica gel powder, powdered beef and glucose
?.
Embodiment 4
The component and its mass percent of the dog of the present embodiment compound Fei Luokao former times dry suspensoid agent are as follows:
Fei Luokao former times 0. 5%；
Glucosamine Sulphate 1.20%；
Calcitriol 1.2 × 10-6%；
Carboxymethyl cellulose 4.0%
Dodecyl sodium sulfate 1.0%；
Superfine silica gel powder 1.0%；
Chicken liver meal 1%；
Duck liver powder 1%
Soluble starch is to 100%.
The dog of the present embodiment compound Fei Luokao former times dry suspensoid agent the preparation method comprises the following steps: above-mentioned former, auxiliary material is distinguished respectively
It sieves with 100 mesh sieve spare, first by Fei Luokao former times, calcitriol and dodecyl sodium sulfate, mixes well, be placed in particle ball mill
Grinding 1 hour is crossed 120 meshes in prescription ratio in this mixture and is entered the sulfuric acid aminoglucose of recipe quantity with equivalent gradually-increased
Sugar, carboxymethyl cellulose, superfine silica gel powder, chicken liver meal, duck liver powder and soluble starch, finally dispense mixture to obtain the final product.
Embodiment 5
The component and its mass percent of the dog of the present embodiment compound Fei Luokao former times dry suspensoid agent are as follows:
Fei Luokao former times 0.5%；
Glucosamine Sulphate 1.32%；
Calcitriol 1.0 × 10-6%；
Carboxymethyl cellulose 3.0%
Lecithin 2.0%；
Superfine silica gel powder 1.0%；
Chicken liver meal 2%；
Soluble starch is to 100%.
The dog of the present embodiment compound Fei Luokao former times dry suspensoid agent the preparation method comprises the following steps: above-mentioned former, auxiliary material is distinguished respectively
It sieves with 100 mesh sieve spare, first by Fei Luokao former times, calcitriol and lecithin, mixes well, it is small to be placed in grinding 1 in particle ball mill
When, 120 meshes, which are crossed, in prescription ratio in this mixture enters Glucosamine Sulphate, the carboxylic first of recipe quantity with equivalent gradually-increased
Base cellulose, superfine silica gel powder, chicken liver meal and soluble starch, finally dispense mixture to obtain the final product.
Embodiment 6
The component and its mass percent of the dog of the present embodiment compound Fei Luokao former times dry suspensoid agent are as follows:
Fei Luokao former times 0.5%；
Glucosamine Sulphate 1.32%；
Calcitriol 1.5 × 10-6%；
Carboxymethyl cellulose 3.0%
Hydroxyethyl cellulose 2.0%
Lecithin 2.0%；
Superfine silica gel powder 1.0%；
Chicken meal 3%；
Soluble starch is to 100%.
The dog of the present embodiment compound Fei Luokao former times dry suspensoid agent the preparation method comprises the following steps: above-mentioned former, auxiliary material is distinguished respectively
It sieves with 100 mesh sieve spare, first by Fei Luokao former times, calcitriol and lecithin, mixes well, it is small to be placed in grinding 1 in particle ball mill
When, 120 meshes, which are crossed, in prescription ratio in this mixture enters Glucosamine Sulphate, the carboxylic first of recipe quantity with equivalent gradually-increased
Base cellulose, hydroxyethyl cellulose, superfine silica gel powder, chicken meal and soluble starch, finally dispense mixture to obtain the final product.
Embodiment 7
The component and its mass percent of the dog of the present embodiment compound Fei Luokao former times dry suspensoid agent are as follows:
Fei Luokao former times 0.5%；
Glucosamine Sulphate 1.32%；
Calcitriol 1.5 × 10-6%；
Hydroxypropyl methyl cellulose 1.2%；
Dodecyl sodium sulfate 0.5%；
Superfine silica gel powder 0.5%；
Chicken liver meal 3%；
Glucose is to 100%.
The dog of the present embodiment compound Fei Luokao former times dry suspensoid agent the preparation method comprises the following steps: above-mentioned former, auxiliary material is distinguished respectively
It sieves with 100 mesh sieve spare, first by Fei Luokao former times, calcitriol and dodecyl sodium sulfate, mixes well, be placed in particle ball mill
Grinding 1 hour is crossed 120 meshes in prescription ratio in this mixture and is entered the sulfuric acid aminoglucose of recipe quantity with equivalent gradually-increased
Sugar, hydroxypropyl methyl cellulose, superfine silica gel powder, chicken liver meal and glucose, finally dispense mixture to obtain the final product.
Embodiment 8
The component and its mass percent of the dog of the present embodiment compound Fei Luokao former times dry suspensoid agent are as follows:
Fei Luokao former times 0.75%；
Glucosamine Sulphate 1.2%；
Calcitriol 1.5 × 10-6%；
Hydroxypropyl methyl cellulose 1.2%；
Dodecyl sodium sulfate 0.5%；
Superfine silica gel powder 0.5%；
Chicken liver meal 3%；
Glucose is to 100%.
The dog of the present embodiment compound Fei Luokao former times dry suspensoid agent the preparation method comprises the following steps: above-mentioned former, auxiliary material is distinguished respectively
It sieves with 100 mesh sieve spare, first by Fei Luokao former times, calcitriol and dodecyl sodium sulfate, mixes well, be placed in particle ball mill
120 meshes are crossed in grinding 1 hour, and in prescription ratio in this mixture, the sulfuric acid amino Portugal of recipe quantity is added with equivalent gradually-increased
Grape sugar, hydroxypropyl methyl cellulose, superfine silica gel powder, chicken liver meal and glucose, finally dispense mixture to obtain the final product.
Embodiment 9
The component and its mass percent of the dog of the present embodiment compound Fei Luokao former times dry suspensoid agent are as follows:
Fei Luokao former times 0.75%；
Glucosamine Sulphate 1.32%；
Calcitriol 1.0 × 10-6%；
Hydroxypropyl methyl cellulose 1.5%；
Dodecyl sodium sulfate 0.5%；
Superfine silica gel powder 0.5%；
Chicken liver meal 3%；
Glucose is to 100%.
The dog of the present embodiment compound Fei Luokao former times dry suspensoid agent the preparation method comprises the following steps: above-mentioned former, auxiliary material is distinguished respectively
It sieves with 100 mesh sieve spare, first by Fei Luokao former times, calcitriol and dodecyl sodium sulfate, mixes well, be placed in particle ball mill
Grinding 1 hour is crossed 120 meshes in prescription ratio in this mixture and is entered the sulfuric acid aminoglucose of recipe quantity with equivalent gradually-increased
Sugar, hydroxypropyl methyl cellulose, superfine silica gel powder, chicken liver meal and glucose, finally dispense mixture to obtain the final product.
Embodiment 10
The component and its mass percent of the dog of the present embodiment compound Fei Luokao former times dry suspensoid agent are as follows:
Fei Luokao former times 0.75%；
Glucosamine Sulphate 1.12%；
Calcitriol 1.5 × 10-6%；
Hydroxypropyl methyl cellulose 1.2%；
Dodecyl sodium sulfate 0.5%；
Superfine silica gel powder 0.5%；
Chicken liver meal 3%；
Glucose is to 100%.
The dog of the present embodiment compound Fei Luokao former times dry suspensoid agent the preparation method comprises the following steps: above-mentioned former, auxiliary material is distinguished respectively
It sieves with 100 mesh sieve spare, first by Fei Luokao former times, calcitriol and dodecyl sodium sulfate, mixes well, be placed in particle ball mill
Grinding 1 hour is crossed 120 meshes in prescription ratio in this mixture and is entered the sulfuric acid aminoglucose of recipe quantity with equivalent gradually-increased
Sugar, hydroxypropyl methyl cellulose, superfine silica gel powder, chicken liver meal and glucose, finally dispense mixture to obtain the final product.
In order to ensure the therapeutic effect of compound Fei Luokao former times dry suspensoid agent of the invention, prescription has been carried out to drug of the present invention
The test such as study on the stability, lanqin oral solutions, following tests example can ensure that drug quality of the present invention is reliable, curative for effect.
Test one: the prescription study on the stability of drug of the present invention
Dry suspensoid agent belongs to suspension, after adding water dispersion, should meet the quality requirement of suspension, and the drug in suspension should be uniform
Dispersion, should not sink rapidly, cake block should not be formed after sedimentation, rapid redisperse is answered after shaking.For the embodiment of the present invention 1~
Fei Luokao former times dry suspensoid agent made from 10, has carried out following quality controling research, comprising: character, sedimentation volumn ratio, weight dispersibility
Deng.
(1) character
Compound Fei Luokao former times dry suspensoid agent made from the embodiment of the present invention 1~10 arrives yellowish-brown powder in faint yellow, is in after adding water
Sticky shape is layered after standing, and the micro- Huang of supernatant, lower layer is light yellow precipitate, restores suspension after oscillation.
(2) sedimentation volumn ratio
According to defined method under " Republic of China Veterinary Pharmacopoeia " 2015 editions suspension items, take compound Fei Luokao former times dry
The mixing of suspension 10g purified water is placed in tool plug graduated cylinder, and record elemental height is H0, is stood after shaking after a certain period of time,
The height of lower layer's milky white precipitate object is H when observation sedimentation face no longer changes, and calculates sedimentation solvent ratio by formula F=H/H0.Knot
Fruit shows that the sedimentation volumn ratio F of Examples 1 to 10 meets regulation.Wherein, the F value of embodiment 7~10 is slightly larger than embodiment 1 ~ 6.
(3) weight dispersibility
After the purifying water dispersion of compound Fei Luokao former times dry suspensoid agent made from Examples 1 to 10,7d is placed in graduated cylinder respectively
Afterwards, measurement weight is dispersed, and suspension made from Examples 1 to 10 is shaken several times after rolling, and graduated cylinder bottom sediment can redisperse
At uniform suspending system, vibration rolling number is fewer, illustrates that weight dispersibility is better.Wherein, the weight dispersibility of embodiment 4,5,6 is slightly poor
In other embodiments.
Test two: the pharmacodynamic test of drug of the present invention
1, experimental animal and modeling
By 42 weight be 3.0 ± 0.5Kg Chinese rural area dog, by weight carry out RANDOMIZED BLOCK DESIGN be divided into blank control group,
Model group, positive controls (commercially available Fei Luokao former times piece) and test group (dry suspensoid agent of 7,8,9,10 prescription of embodiment), altogether
Count 7 groups, every group 6.In addition to blank control group, 4% papain of the right knee joint cavity injection 0.5ml of dog establishes Bones and joints
Scorching model.After model is successfully established, test group feeds the dry suspensoid agent in embodiment 7,8,9,10 respectively, by per kilogram of body weight 1g
Preparation is used in conjunction 5 days and is administered once a day.Positive controls are raised after being calculated by per kilogram of body weight 5mg Fei Luokao former times
Feed the tablet.The glucose of blank group and model group feeding equivalent.It is (continuous to use in the 0th day (after model foundation success) and the 5th day
After medicine 5 days) with range of motion, pain, stiff 3 projects, it is divided into asymptomatic, slight, moderate, severe according to severity,
0 point, 1 point, 2 points, 3 points are successively denoted as, the higher symptom that scores is more serious (retaining 1 decimal when test data sheet).
(2) result record and analysis
Test result is as shown in table 1.
The pretherapy and post-treatment symptom score of 1 each group of table (dividing)
Note: it is compared with blank control group, *P< 0.05, this group is interior and treatment is preceding compares, △ P < 0.05
From result above as it can be seen that model group injects 4% papain of 0.5ml by the right knee joint cavity of dog, range of motion,
Pain, the scoring of stiff three indexs dramatically increase, and are determined as model foundation success.Positive controls (marketed tablet), medication 5
Before its posterior joint mobility, pain, the scoring of stiff three indexs are substantially less than medication, preferable therapeutic effect is showed, but
It is to show not restore to normal there are still significant difference compared with blank group.7,8,9,10 prescription of embodiment it is dry-mixed
Suspension group shows preferable before 5 days posterior joint mobilities of medication, pain, the scoring of stiff three indexs are substantially less than medication
Therapeutic effect, wherein 7 range of motion of embodiment and it is stiff between blank control group without significant difference, 8 joint of embodiment is living
Without significant difference between dynamic degree and blank control group, show after the drug therapy of the prescription, it is basic to restore to normal.Embodiment
Although 7, the three indexs scoring of the dry suspensoid agent group of 8,9,10 prescriptions after the treatment is not significant with positive controls difference, whole
Body scoring has different degrees of decline.Comprehensive analysis, the dry suspensoid agent of 7,8,9,10 prescription of embodiment is in the Bones and joints for treating dog
There is good therapeutic effect in inflammation, and be better than Fei Luokao former times piece.In addition, all test groups do not occur gastrointestinal symptom etc. no
Good reaction tentatively shows all prescription good securities.
Finally, it is stated that preferred embodiment above is only used to illustrate the technical scheme of the present invention and not to limit it, although logical
It crosses above preferred embodiment the present invention is described in detail, however, those skilled in the art should understand that, can be
Various changes are made to it in form and in details, without departing from claims of the present invention limited range.
Claims (7)
1. a kind of dog composition of compound Fei Luokao former times dry suspensoid agent, which is characterized in that it is by Antiarthritic, arthralgic non-
Sieve examines former times, promotes the Glucosamine Sulphate of regenerating bone or cartilage, increases bone calcium and stores the ossification three to shield to articular cartilage
Alcohol, these three active constituents composition, main component and its mass percent are as follows:
Fei Luokao former times 0.25 ~ 0.75%；
Glucosamine Sulphate 1.12 ~ 1.32%；
Calcitriol 1.0 ~ 1.5 × 10-6%；
Suspending agent 0.8 ~ 4%；
Surfactant 0.25 ~ 1%；
Glidant 0.5 ~ 1%；
Corrigent 1 ~ 3%；
Filler is to 100%.
2. dog according to claim 1 compound Fei Luokao former times dry suspensoid agent, it is characterised in that: the suspending agent is hydroxyl
One or both of propyl methocel, hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose.
3. dog according to claim 1 compound Fei Luokao former times dry suspensoid agent, it is characterised in that: the surfactant is
One of dodecyl sodium sulfate, Tween-80, lecithin.
4. dog according to claim 1 compound Fei Luokao former times dry suspensoid agent, it is characterised in that: the glidant is micro-
One of powder silica gel, talcum powder.
5. dog according to claim 1 compound Fei Luokao former times dry suspensoid agent, it is characterised in that: the corrigent is ox
One or both of digested tankage, chicken meal, chicken liver meal, duck liver powder.
6. dog according to claim 1 compound Fei Luokao former times dry suspensoid agent, it is characterised in that: the filler is Portugal
One of grape sugar and soluble starch.
7. the preparation method of compound Fei Luokao former times dry suspensoid agent of dog described in claim 1 to 6 any one, feature exist
In: former, auxiliary material is sieved with 100 mesh sieve respectively, first by Fei Luokao former times, calcitriol and surfactant, mixes well, is placed in particle
It is ground 1 hour in ball mill, crosses 120 meshes in prescription ratio in this mixture and sulfuric acid aminoglucose is entered with equivalent gradually-increased
Sugar, suspending agent, glidant, corrigent and filler, finally dispense mixture to obtain the final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810995280.2A CN109045023A (en) | 2018-08-29 | 2018-08-29 | A kind of dog compound Fei Luokao former times dry suspensoid agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810995280.2A CN109045023A (en) | 2018-08-29 | 2018-08-29 | A kind of dog compound Fei Luokao former times dry suspensoid agent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109045023A true CN109045023A (en) | 2018-12-21 |
Family
ID=64756462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810995280.2A Pending CN109045023A (en) | 2018-08-29 | 2018-08-29 | A kind of dog compound Fei Luokao former times dry suspensoid agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109045023A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1621044A (en) * | 2003-11-24 | 2005-06-01 | 山东绿叶制药集团有限公司 | Composition for preventing and treating arthritis, formulation containing said composition, its preparation process and usage |
| CN1964715A (en) * | 2004-05-06 | 2007-05-16 | 默克公司 | Methods for treating arthritic conditions in dogs |
| CN102525974A (en) * | 2011-08-31 | 2012-07-04 | 南京仕必得生物技术有限公司 | Meloxicam tablets for dogs and cats and preparation method for meloxicam tablets |
| CN103110587A (en) * | 2013-02-19 | 2013-05-22 | 青岛正大海尔制药有限公司 | Alfacalcidol dry suspension and preparation method thereof |
| WO2014052640A1 (en) * | 2012-09-28 | 2014-04-03 | Ronald Plante Paul | Novel ampk agonist compositions and methods of use |
| US20160158222A1 (en) * | 2010-04-29 | 2016-06-09 | Allodynic Therapeutics, Inc. | Combinations of opioid/tlr4 antagonist and a cyclooxygenase (cox) inhibitor for use in the treatment of pain |
-
2018
- 2018-08-29 CN CN201810995280.2A patent/CN109045023A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1621044A (en) * | 2003-11-24 | 2005-06-01 | 山东绿叶制药集团有限公司 | Composition for preventing and treating arthritis, formulation containing said composition, its preparation process and usage |
| CN1964715A (en) * | 2004-05-06 | 2007-05-16 | 默克公司 | Methods for treating arthritic conditions in dogs |
| US20160158222A1 (en) * | 2010-04-29 | 2016-06-09 | Allodynic Therapeutics, Inc. | Combinations of opioid/tlr4 antagonist and a cyclooxygenase (cox) inhibitor for use in the treatment of pain |
| CN102525974A (en) * | 2011-08-31 | 2012-07-04 | 南京仕必得生物技术有限公司 | Meloxicam tablets for dogs and cats and preparation method for meloxicam tablets |
| WO2014052640A1 (en) * | 2012-09-28 | 2014-04-03 | Ronald Plante Paul | Novel ampk agonist compositions and methods of use |
| CN103110587A (en) * | 2013-02-19 | 2013-05-22 | 青岛正大海尔制药有限公司 | Alfacalcidol dry suspension and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 张佳慧等: "骨关节炎合并骨质疏松症及其药物干预的研究进展", 《风湿病与关节炎》 * |
| 张新萍主编: "《内科安全用药监护手册》", 31 March 2013 * |
| 王敏等: "美洛昔康干混悬剂的制备及其处方因素考察", 《遵义医学院学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101022789A (en) | A combination composition | |
| JP6637937B2 (en) | Capsule preparation and powder preparation containing lanthanum compound | |
| CN101559218B (en) | Composition with function of increasing bone density | |
| RU2002106748A (en) | Tramadol Pharmaceutical Salts | |
| CN1092973C (en) | Use of incense in the treatment of alzheimer's disease | |
| CN102949710A (en) | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product | |
| CN101057862A (en) | Medicinal composition for treating senile osteoarthropathy | |
| CN1806800A (en) | Pharmaceutical composition making pregabalin as active ingredient, its preparation method and uses | |
| CN106389344A (en) | Calcium carbonate particles and preparation method thereof | |
| JP2002512979A (en) | Homogeneous pharmaceutical composition comprising abaca beer, lamivudine and zidovudine | |
| CN110507620A (en) | A kind of compound glucosamine sulfate dispersible tablet and preparation method thereof | |
| CN100528150C (en) | Novel pharmaceutical formulations of modafinil | |
| CN108741099A (en) | One kind contributing to comfortable alimentation composition in joint and its preparation method and application | |
| CN106109490A (en) | One increases bone density, prevents and treats osteoporotic tablet and preparation method thereof | |
| CN1823764A (en) | Medicinal composition containing strontium fuminate and vitamin D | |
| CN109045023A (en) | A kind of dog compound Fei Luokao former times dry suspensoid agent and preparation method thereof | |
| CN110946994A (en) | Composition for increasing bone mineral density and preparation method thereof | |
| WO2001012200A1 (en) | An oral composition comprising coenzyme a for treating hyperlipemia, the preparation method and the use thereof | |
| CN110214947A (en) | A kind of prevention and treatment osteoarthritis composition | |
| CN109464651A (en) | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine | |
| CN1364464A (en) | Aminoglucose hydrochloride medicinal composition | |
| CN102000110A (en) | Composition used for preventing or treating bone and joint diseases and preparation method thereof | |
| CN103520267A (en) | Wettable experimental pullorum evapotranspiration and preparation method thereof | |
| CN1820783A (en) | Thyroid hormone medicinal preparation | |
| JP2004535455A (en) | Calcium L-threonate for preventing or treating cartilage-related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181221 |
|
| RJ01 | Rejection of invention patent application after publication |